MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-023-02631-x

Медицинская библиотека · Nature medicine · 2023

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

Fraterman Itske, Reijers Irene L M, Dimitriadis Petros, Broeks Annegien, Gonzalez M, Menzies A M M, Lopez-Yurda Marta, Kapiteijn Ellen, van der Veldt Astrid A M, Suijkerbuijk Karijn P M, Hospers Geke A P, Long Georgina V, Blank Christian U, van de Poll-Franse Lonneke V

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Neoadjuvant immune checkpoint blockade (ICB) outperforms adjuvant ICB for treatment of stage IIIB-D melanoma, but potential biomarkers of response, such as interferon-gamma (IFNγ) signature and tumor mutational burden (TMB), are insufficient. Preclinical studies suggest that emotional distress (ED) can negatively affect antitumor immune responses via β-adrenergic or glucocorticoid signaling. We performed a post hoc analysis evaluating the association between pretreatment ED and clinical responses after neoadjuvant ICB treatment in patients with stage IIIB-D melanoma in the phase 2 PRADO trial ( NCT02977052 ). The European Organisation for Research and Treatment of Cancer scale for emotional functioning was used to identify patients with ED (n = 28) versus those without (n = 60). Pretreatment ED was significantly associated with reduced major pathologic responses (46% versus 65%, adjusted odds ratio 0.20, P = 0.038) after adjusting for IFNγ signature and TMB, reduced 2-year relapse-free survival (74% versus 91%, adjusted hazard ratio 3.81, P = 0.034) and reduced 2-year distant metastasis-free survival (78% versus 95%, adjusted hazard ratio 4.33, P = 0.040) after adjusting for IFNγ signature. RNA sequencing analyses of baseline patient samples could not identify clear β-adrenergic- or glucocorticoid-driven mechanisms associated with these reduced outcomes. Pretreatment ED may be a marker associated with clinical responses after neoadjuvant ICB in melanoma and warrants further investigation. ClinicalTrials.gov registration: NCT02977052 .

Для цитирования: Fraterman Itske, Reijers Irene L M, Dimitriadis Petros, Broeks Annegien, Gonzalez M, Menzies A M M, Lopez-Yurda Marta, Kapiteijn Ellen, van der Veldt Astrid A M, Suijkerbuijk Karijn P M, Hospers Geke A P, Long Georgina V, Blank Christian U, van de Poll-Franse Lonneke V. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.. Nature medicine. 2023. DOI: 10.1038/s41591-023-02631-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.